Retraction: High Mobility Group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity (Cell Death and Differentiation (2006) 13 (1554-1563) DOI: 10.1038/sj.cdd.4401839);High Mobility Group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity

Cell Death and Differentiation

Volumn 13, Issue 9, 2006, Pages 1554-1563

  Pierantoni, G M ^a   Rinaldo, C ^b   Esposito, F ^a   Mottolese, M ^b   Soddu, S ^b   Fusco, A ^a,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; HIGH MOBILITY GROUP A PROTEIN; HIGH MOBILITY GROUP A1 PROTEIN; PROTEIN BAX; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; ULTRAVIOLET RADIATION;

EID: 33747057745     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.183     Document Type: Erratum

References (39)

1. Grosschedl R, Giese K and Pagel J (1994) HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. Trends Genet. 10: 38-42
2. Reeves R (2000) Structure and function of the HMGI(Y) family of architectural transcription factors. Environ. Health Perspect. 108: 803-809
3. Reeves R and Nissen MS (1990) The A-T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J. Biol. Chem. 265: 8573-85782
4. Thanos D and Maniatis T (1995) Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. Cell 83: 1091-1100
5. Zhou X, Benson KF, Asher HR and Chada K (1995) Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 376: 771-774
6. Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti V, Santoro M, Simeone A and Fusco A (1996) High level expression of the HMGA1 gene during embryonic development. Oncogene 13: 2439-2446
7. Giancotti V, Berlingieri MT, Di Fiore PP, Fusco A, Vecchio G and Crane-Robinson C (1985) Changes in nuclear proteins on transformation of rat epithelial thyroid cells by a murine sarcoma retrovirus. Cancer Res. 45: 6051-6057
8. Giancotti V, Pani B, D'Andrea P, Berlingieri MT, Di Fiore PP, Fusco A, Vecchio G, Philp R, Crane-Robinson C and Nicolas RH (1987) Elevated levels of a specific class of nuclear phosphoroproteins in cells transformed with ras and v-mos oncogenes and by co-transfection with c-myc and Polyoma Middle T genes. EMBO J. 6: 1981-1987
9. Giancotti V, Buratti E, Perissin L, Zorzet S, Balmain A, Portella G, Fusco A and Goodwin GH (1989) Analysis of the HMGI nuclear proteins in mouse neoplastic cells induced by different procedures. Exp. Cell Res. 184: 538-545
10. Chiappetta G, Bandiera A, Berlingieri MT, Visconti R, Manfioletti G, Battista S, Martinez-Tello FJ, Santoro M, Giancotti V and Fusco A (1995) The expression of the high mobility group HMGA1 proteins correlates with the malignant phenotype of human thyroid neoplasms. Oncogene 10: 1307-1314
11. Chiappetta G, Tallini G, De Biasio MC, Manfioletti G, Martinez-Tello FJ, Pentimalli F, de Nigris F, Mastro A, Botti G, Fedele M, Berger N, Santoro M, Giancotti V and Fusco A (1998) Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res. 58: 4193-4198
12. Fedele M, Bandiera A, Chiappetta G, Battista S, Viglietto G, Manfioletti G, Casamassimi A, Santoro M, Giancotti V and Fusco A (1996) Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res. 56: 1896-1901
13. Abe N, Watanabe T, Sugiyama M, Uchimura H, Chiappetta G, Fusco A and Atomi Y (1999) Determination of high mobility group I(Y) expression level in colorectal neoplasias: A potential diagnostic marker. Cancer Res. 59: 1169-1174
14. Chiappetta G, Manfioletti G, Pentimalli F, Abe N, Di Bonito M, Vento MT, Giuliano A, Fedele M, Viglietto G, Santoro M, Watanabe T, Giancotti V and Fusco A (2001) High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. Int. J. Cancer 91: 147-151
15. Tamimi Y, van der Poel HG, Denyn MM, Umbas R, Karthaus HF, Debruyne FM and Schalken JA (1993) Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. Cancer Res. 53: 5512-5516
16. Abe N, Watanabe T, Izumisato Y, Masaki T, Mori T, Sugiyama M, Chiappetta G, Fusco A, Fujioka Y and Atomi Y (2002) Diagnostic significance of high mobility group I(Y) protein expression in intraductal papillary mucinous tumors of the pancreas. Pancreas 25: 198-204
17. Bandiera A, Bonifacio D, Manfioletti G, Mantovani F, Rustighi A, Zanconati F, Fusco A, Di Bonito L and Giancotti V (1998) Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix. Cancer Res. 58: 426-431
18. Masciullo V, Baldassarre G, Pentimalli F, Berlingieri MT, Boccia A, Chiappetta G, Palazzo J, Manfioletti G, Giancotti V, Viglietto G, Scambia G and Fusco A (2003) HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis 24: 1191-1198
19. Baldassarre G, Battista S, Belletti B, Thakur S, Pentimalli F, Trapasso F, Fedele M, Pierantoni G, Croce CM and Fusco A (2003) Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol. Cell. Biol. 23: 2225-2238
20. Berlingieri MT, Manfioletti G, Santoro M, Bandiera A, Visconti R, Giancotti V and Fusco A (1995) Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol. Cell. Biol. 15: 1545-1553
21. Berlingieri MT, Pierantoni GM, Giancotti V, Santoro M and Fusco A (2002) Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene 21: 2971-2980
22. Scala S, Portella G, Fedele M, Chiappetta G and Fusco A (2000) Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc. Natl. Acad. Sci. USA 11: 4256-4261
23. Lane DP (1992) Cancer: P53, guardian of the genome. Nature 358: 15-16
24. Vousden KH (2000) p53: Death star. Cell 103: 691-694
25. Vogelstein B, Lane D and Levine AJ (2000) Surfing the p53 network. Nature 408: 307-310
26. Schmitt CA, Fridman JS, Yang M, Baranov E, Hofmann RM and Lowe SW (2002) Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1: 289-298
27. Gottlieb TM and Oren M (1996) p53 in growth control and neoplasia. Biochim. Biophys. Acta 1287: 77-102; Review
28. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH and Levine AJ (2000) Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev. 14: 981-993
29. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501
30. Hupp TR, Meek DW, Midgley CA and Lane DP (1992) Regulation of the specific DNA binding function of p53. Cell 71: 875-886
31. Ito T (1992) Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52: 1369-1371
32. Gao X, Porter AT, Grignon DJ, Pontes JE and Honn KV (1997) Diagnostic and prognostic markers for human prostate cancer. Prostate 31: 264-281
33. Jayaraman L, Moorthy NC, Murthy KG, Manley JL, Bustin M and Prives C (1998) High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev. 15: 462-472
34. Stros M, Ozaki T, Bacikova A, Kageyama H and Nakagawara A (2002) HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J. Biol. Chem. 277: 7157-7164
35. Bustin M and Reeves R (1996) High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog. Nucleic Acid Res. Mol. Biol. 54: 35-100. Review.
36. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, Piaggio G, Fanciulli M, Appella E and Soddu S (2002) Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 4: 11-19
37. Pierantoni GM, Fedele M, Pentimalli F, Benvenuto G, Pero R, Viglietto G, Santoro M, Chianotti L and Fusco A (2001) High mobility group I(Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth. Oncogene. 20: 6132-6141
38. Bacchetti S and Graham F (1993) Inhibition of cell proliferation by an adenovirus vector expressing the human wild type p53 protein. Int. J. Oncol. 3: 781-788
39. D'Orazi G, Marchetti A, Crescenzi M, Coen S, Sacchi A and Soddu S (2000) Exogenous wt-p53 protein is active in transformed cells but not in their non-transformed counterparts: Implications for cancer gene therapy without tumor targeting. J. Gene Med. 2: 11-21